



IMD - Institut für Medizinische Diagnostik launches the GA-map® Microbiome Test in Germany

OSLO, NORWAY/BERLIN, GERMANY – 15 February 2022: Microbiome DX company Genetic Analysis AS (“GA”) and Institut für Medizinische Diagnostik (“IMD”), a part of the Medicover Group, announces today that IMD has launched the GA-map® Dysbiosis Test in Germany. IMD will activate its new Microbiome laboratory in February 2022 and add standardized microbiota testing to its existing test portfolio of products. This new Microbiota test offering will be marketed to customers in Germany and Europe.

In 2021, Genetic Analysis launched the updated version of GA-map® Dysbiosis Test – the first CE-marked IVD test on the market providing microbiota profiles and dysbiosis status for IBS and IBD patients. The standardized GA-map® Technology platform is based on an innovative Pre-Determined Targets approach (PDT) and is a valuable tool both in clinical research and routine diagnostics.

Medical Director of IMD, Dr. Volker von Baehr, comments:

“IMD is an expert laboratory in the field with a focus on high-quality results. We are proud to be offering the CE-certified GA-map® test panel to our customers. The GA-map® Dysbiosis Test is measuring the abundance of clinically relevant key bacteria in relation to a clinically defined, healthy, normal population. This is a major difference from other sequencing methods where each user must establish their own reference ranges for healthy and diseased cohorts. Focusing on the clinically relevant key bacteria will save both time and resources, and the GA-map® platform is demonstrating excellent performance and efficiency in our laboratory.”

CEO of Genetic Analysis, Ronny Hermansen, comments:

“We are proud to partner up with IMD and power their laboratory with the unique CE-marked GA-map® platform. The GA-map® uses the high-quality Luminex®200 and MAGPIX® readout instruments, ensuring an efficient and high-quality workstream for the Laboratory customer. IMD, through the Medicover Group, has a strong European footprint in clinical and research diagnostics, and it is GA’s strategy to supply high-volume clinical laboratories with superb quality diagnostics solutions that save time and cost for the laboratories and provides accurate results.”

For more information on Genetic Analysis, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

For more information on IMD / Medicover Group, please contact:

<https://www.imd-berlin.de/service-kontakt/kontaktformular>

This information is such information that Genetic Analysis AS is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on 15 February 2022.

About Genetic Analysis

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-targeted multiplex approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting-edge GA-map® software

algorithm. This enables immediate results without the need for further bioinformatics work. GA's vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to helping to unlock and restore the human microbiome through its state-of-the-art technology. GA employs 23 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering.

For more information visit the Genetic Analysis website: www.genetic-analysis.com

About IMD Laboratory Berlin

The Institute for Medical Diagnostics Berlin has more than 400 employees and conducts investigations in the fields of laboratory medicine, microbiology, molecular diagnostics, and transfusion medicine. The high-quality standards and the quality assurance of our laboratory services ensure that IMD meets its responsibilities to medical practices, customers, service providers, and employees. Through the continuous improvement of its technology as well as the expansion of methodology, the efficient adaptation of processes, and professional competence, IMD meets the constantly changing quality requirements. These efforts are recognised by accreditation by the Deutsche Akkreditierungsstelle GmbH (DAKKS).

For more information visit the IMD Institut für Medizinische Diagnostik Berlin-Potsdam (MVZ) GbR Laboratory website: <https://www.imd-berlin.de>

About Medicovert Group

Medicovert is a leading international healthcare and diagnostic services company and was founded in 1995. Medicovert operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories, and blood-drawing points, and the largest markets are Poland and Germany.

For more information visit the Medicovert website: www.medicovert.com